BioNevia LLC is a clinical stage biotechnology company focused on developing drugs for the treatment of diabetes-associated diseases. Founded in 2007, BioNevia is focused on the development and commercialization of products for the treatment of unmet medical needs in the field of diabetes and related diseases. According to recent reports by the World Health Organization (WHO), diabetes has become epidemic in both developed and non-developed countries throughout the world, affecting more than 380 million people worldwide, with more than 29 million in the US alone. This number is expected to grow to 420 million people with diabetes by 2025.
The Company’s lead compound, BNV-222, is a potential first-in-class, disease-modifying treatment for slowing or arresting diabetic peripheral neuropathy (DPN), a progressive debilitating complication of diabetes. Based on its mechanism of action, BNV-222 also has potential to be effective in other diabetic complications such as nephropathy and retinopathy.